Tirzepatide 1-Year Results: Long-Term Data
Review 1-year tirzepatide results from SURMOUNT clinical trials including weight loss outcomes, metabolic improvements, side effect profiles, and what happens after year one.
More on Tirzepatide
Medical Disclaimer
This article summarizes clinical trial data for educational purposes. Individual results vary. Clinical trial participants are monitored under controlled conditions that may differ from real-world use. Consult your healthcare provider for personalized expectations.
SURMOUNT Trial Results at 72 Weeks
The SURMOUNT-1 trial enrolled 2,539 adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity. Participants were randomized to tirzepatide 5mg, 10mg, 15mg, or placebo, with all groups receiving lifestyle counseling.
Tirzepatide 5mg
Average weight loss: 15.0% of body weight (34 lbs from 231-lb baseline). 85% of participants achieved at least 5% weight loss. 69% achieved at least 10%. 34% achieved at least 20%.
Tirzepatide 10mg
Average weight loss: 19.5% of body weight (45 lbs from 231-lb baseline). 89% achieved at least 5%. 78% achieved at least 10%. 50% achieved at least 20%.
Tirzepatide 15mg
Average weight loss: 22.5% of body weight (52 lbs from 231-lb baseline). 91% achieved at least 5%. 84% achieved at least 10%. 57% achieved at least 20%. 36% achieved at least 25%.
Placebo
Average weight loss: 3.1% of body weight with lifestyle counseling alone.
Health Improvements Beyond Weight
Cardiovascular Markers
Systolic blood pressure decreased 6-9 mmHg. Triglycerides reduced 25-30%. LDL cholesterol decreased 5-10%. HDL cholesterol increased 5-8%. These improvements significantly reduce estimated 10-year cardiovascular risk.
Metabolic Health
Fasting glucose decreased 15-25 mg/dL. Fasting insulin decreased 40-60%. HbA1c decreased 0.5-0.7% in non-diabetic participants. In diabetic participants (SURPASS trials), HbA1c reductions of 2.1-2.6% were observed.
Inflammatory Markers
CRP (C-reactive protein) decreased by 35-50%, indicating significant reduction in systemic inflammation. This reduction is associated with lower risk of cardiovascular events, cancer, and other inflammation-driven diseases.
Quality of Life
IWQOL-Lite scores improved significantly across all domains: physical function, self-esteem, sexual life, public distress, and work. Physical function improvements were particularly dramatic, with many patients reporting activities they had been unable to do for years.
What Happens After Year One
The SURMOUNT-4 trial addressed the critical question of what happens when tirzepatide is discontinued. Participants who achieved at least 5% weight loss on tirzepatide were randomized to continue treatment or switch to placebo. The continuation group maintained their weight loss and continued to lose modestly, while the placebo group regained approximately two-thirds of lost weight over 52 weeks.
This data reinforces that tirzepatide addresses the biology of obesity (hormonal imbalances, metabolic adaptation) but does not cure the underlying condition. Continued treatment is typically necessary for sustained results, similar to how blood pressure or cholesterol medications require ongoing use. Compounded tirzepatide through Trimi at $125/month makes long-term treatment more accessible.
Frequently Asked Questions
How much weight do people lose after 1 year on tirzepatide?
In the SURMOUNT-1 trial (72 weeks), average weight loss was 15% at 5mg, 19.5% at 10mg, and 22.5% at 15mg. For a 230-pound participant, this translates to roughly 34-52 pounds. Approximately 36% of patients on 15mg lost 25% or more of body weight, and some patients achieved weight loss exceeding 30%.
Do tirzepatide results plateau after 1 year?
Weight loss does slow significantly by month 12-15 as the body reaches a new equilibrium. However, the weight lost is maintained as long as the medication continues. The SURMOUNT-3 and -4 trials showed that discontinuing tirzepatide after reaching target weight resulted in significant weight regain, reinforcing the importance of continued treatment for maintenance.
What health improvements occur after 1 year on tirzepatide?
Beyond weight loss, 1-year data shows: HbA1c reduction of 2.1-2.6% in diabetic patients, systolic blood pressure reduction of 6-9 mmHg, triglyceride reduction of 25-30%, improvements in sleep apnea severity, reduced liver fat, and improved quality of life scores across all domains.
Is tirzepatide safe for long-term use?
Current data extending up to 2 years shows a stable safety profile. Side effects decrease over time as the body adjusts. The most common GI side effects (nausea, diarrhea, constipation) are primarily an issue during dose escalation. Long-term monitoring studies are ongoing to evaluate safety beyond 2 years.
Begin Your Transformation
Join thousands achieving significant, sustained weight loss. Compounded tirzepatide from $125/month.
Explore Treatment OptionsSources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).